BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential

July 17, 2026 5:10 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $28.00 price target on BioCryst Pharma (NASDAQ: BCRX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found